The global sales of Atopic Dermatitis Treatment is estimated to be worth USD 15.04 billion in 2024 and anticipated to reach a value of USD 45.50 billion by 2034. Sales are projected to rise at a CAGR of 11.7% over the forecast period between 2024 and 2034. The revenue generated by Atopic Dermatitis Treatment cover in 2023 was USD 13,441.4 million. The industry is anticipated to exhibit a Y-o-Y growth of 12.0% in 2024.
Atopic dermatitis, also known as eczema, is a chronic inflammatory skin disorder characterized by dry, itchy, and inflamed skin. A combination of indicators contributes towards developing Atopic dermatitis includes genetic inclination, very weak immune system, stress along with environmental factors such as irritants and allergens.
It is predominant among children at early childhood are few of the cause of atopic dermatitis. Some common environmental factors include usage of soaps and detergents, few foods that can exacerbate the symptoms and worsen the condition. The treatment is purely based on keeping the moisture content of the skin to optimal, eliminating triggering events, and drug therapy aimed at reducing inflammation and itching.
Global Atopic Dermatitis Treatment Industry Assessment
| Attributes | Key Insights |
|---|---|
| Historical Size, 2023 | USD 13,441.4 million |
| Estimated Size, 2024 | USD 15.04 billion |
| Projected Size, 2034 | USD 45.50 billion |
| Value-based CAGR (2024 to 2034) | 11.7% |
The prevalence of atopic dermatitis has visibly been increasing all over the world, which is related to several environmental and lifestyle factors. These increasing prevalence, has significantly contributed to an increasing demand for effective treatments and management strategies.
This rising demand has encouraged pharmaceutical companies to develop innovation in products, such as biologics with specific immune pathways, and improvement in topical which improve the symptoms such as itching and inflammation better.
These growing innovation not only improves the patient outcomes but also aid pharmaceutical manufacturers in expansion of their market presence, which in turn augments the growth of the market.
The Atopic Dermatitis Treatment market is set to experience an optimum growth of 11.7% during the forecast period. It is projected to create an incremental opportunity of USD 30,453.0 million and is predicted to rise 3 times the current market value through 2034.
In addition, raising awareness and diagnostic development for the early detection and treatment of atopic dermatitis, further boosts the market growth.
The pharmaceutical industries focus on development of new therapies for the treatment of the atopic dermatitis condition along with the increase in number of new entrant players who have accelerated the development and introduction advanced treatment option for the disease anticipates the market growth. Therefore, the increasing investment made in research and development, for drug innovation further drives the market growth.
The table below provides a detailed comparison of the Compound Annual Growth Rate (CAGR) variations for the global atopic dermatitis market, spanning from the base year (2023) to the current year (2024) over the first half of the year.
This analysis highlights significant shifts in market dynamics and identifies key trends in revenue generation, offering stakeholders crucial insights into the market's progression over the examined period. The first half (H1) includes January to June, while the second half (H2) comprises July to December.
| Particular | Value CAGR |
|---|---|
| H1 | 7.3% (2023 to 2033) |
| H2 | 12.3% (2023 to 2033) |
| H1 | 11.7% (2024 to 2034) |
| H2 | 11.4% (2024 to 2034) |
In the first half (H1) of the decade from 2023 to 2033, the business is predicted to surge at a CAGR of 7.3%, followed by a increase in growth rate of 12.3% in the second half (H2) of the same decade.
Moving into the subsequent period, from H1 2024 to H2 2034, the CAGR is projected to increase slightly to 11.7% in the first half and remain relatively moderate at 11.4% in the second half. In the first half (H1) the market witnessed an increase of 440 BPS while in the second half (H2), the market witnessed a decrease of 90 BPS.
Growing Demand for Effective Therapies of Atopic Dermatitis Surges the Market Growth
The high demand for effective therapies to treat atopic dermatitis is driven by several factors, all converging to meet the needs of a growing patient population. Atopic dermatitis is a common, chronic inflammatory skin condition whose classic symptoms of itching, dryness, and inflammation of the skin cause great discomfort and impairment in the quality of life of patients of any age group.
The growing awareness of disease among patients and professionals has significantly contributed to the growing demand of treatment options that not only reduces disease mechanism but also target and act on disease mechanism.
To meet this growing demand many of the manufacturers are focusing on development of biologic therapies that are promising in treatment of the disease from moderate to severe degree. These therapies are targeted against specific immune pathways that can relieve the symptoms and avoid any side effects as compared to traditional treatments.
Manufacturers are also emphasizing on development of topical treatments that have wide spectrum of action against the disease.
Therefore, the growing advocacy of patients, and healthcare providers on rising prevalence of atopic dermatitis has mainly contributed to the growing demand of drugs that are effective. These factor have also encouraged manufacturers to make investment towards development of new drugs that have utmost efficacy and limited side effects.
These factors demonstrates that new therapies will continuously be emerging to meet evolving challenges, improving outcomes for patients and contribute to the growth of the market.
Advancements in the Treatment of Atopic Dermatitis Provides Growth Opportunities
There is a significant investment among pharmaceutical companies with regards to drug development to bring therapies with increased efficacy, safety, and convenience into the market. Biologic therapies, including monoclonal antibodies against selectively highlighted inflammatory pathways such as IL-4 and IL-13, creates a subset of these meaningful developments.
These treatments has to offer more targeted relief for cases of moderate to severe atopic dermatitis where traditional therapies have fallen short. For instance, in June 2024, LEO Pharma Inc., received approval for the use of Adbry (tralokinumab-ldrm), in adult patients. The drug is a single-dose autoinjector which is indicated for treatment of atopic dermatitis.
Innovation in topical methods, includes new formulations that enforce skin barrier function and reduce any inflammation without the problems of corticosteroid therapy. Calcineurin inhibitors represent a non-steroidal approach with alternative options for long-term treatments of sensitive areas or purposes of maintenance therapy.
Moreover, research and development of combination therapies targeting inflammation and skin barrier dysfunction are emerging which probably may gain traction in the near future. Therefore, the growing focus of manufacturers on conducting robust clinical trials for the development of new therapeutic products indicated for atopic dermatitis majorly augments the growth of the market.
Strategic Collaborations for Research and Development of Atopic Dermatitis Products Propels its Market Growth
Pharmaceutical companies partner with academic partners for sophisticated research, expertise in dermatological issues, and leading pre-clinical models of drug discovery. These collaborations allow for the validation of potential drug targets and pathways with early-stage data, paving the way for acceleration in the translation of scientific discoveries into the clinic.
Collaborations plays an important role in the development of atopic dermatitis products are of utmost importance in the development of treatment options for chronic skin condition. It help companies to exchange their knowledge for certain products that is of both of their interests.
These collaborations are aimed to accelerate the research and development process. For instance, in January 2023, Amgen Inc., collaborated with Kyowa Kirin, a Japanese pharmaceutical company for accelerating the investigation of safety and efficacy of rocatinlimab for moderate to severe atopic dermatitis. The company has begun recruiting participants for their global phase 3 under its ROCKET program.
Biotech companies team up with larger pharmaceutical companies to move novel biologics such as monoclonal antibodies against certain immune pathways. These pathways are already known, or are hypothesized, to become engaged in atopic dermatitis.
For instance, in January 2020, Almirall, S.A, a skin health focused pharmaceutical company collaborated with WuXi Biologics for the development of highly innovative biologic products indicated for dermatology diseases such as atopic dermatitis.
These strategic collaborations develop collaborative environment which accelerates innovation and build high chances of developing effective treatments against atopic dermatitis.
Availability of Alternative Treatment Options Constrains the growth of Atopic Dermatitis Treatment market
Many patients and health care providers are turning to over-the-counter products such as moisturizers, emollients, and anti-itch creams. The major reason for this preferential shift is due to its wide availability, inexpensive nature, and safety profile. These factors make them a more attractive option compared to expensive prescription therapies.
Moreover, increasing interest in natural and holistic modes of treatment has had an adverse effect on the market. More than ever before, patients look toward herbal remedies, dietary alterations, and non-pharmacological interventions like phototherapy and acupuncture in the management of symptoms.
Such options are often viewed as more natural or less invasive and thus meet the demand from patients for less harsh therapy, even where they may not be similarly efficacious to the newer prescription medications available.
Another reason patients turn to these alternatives is the unwillingness to be treated with prescriptions, mostly due to concerns over side effects from the chronic use of corticosteroids and immunosuppressant’s.
This shift in preference away from these conventional medications consequently lowers the total demand for the more advanced and newer treatments, thereby limiting the growth in the atopic dermatitis treatment market amidst an increasing prevalence of atopic dermatitis diseases.
The global Atopic Dermatitis Treatment cover industry recorded a CAGR of 11.7% during the historical period between 2019 and 2023. The growth of Atopic Dermatitis Treatment cover industry was positive as it reached a value of USD 13,441.4 million in 2023 from 8,601 million in 2019.
Atopic dermatitis is a skin condition which are characterized by the presence of dry and itchy skin, which if left untreated can cause serious skin infection. For instance, according to an article published by International Eczema Council in 2022, atopic dermatitis marks over 20% of the children across the globe and is ranked 15th worldwide for non-fatal skin disease.
This makes the early diagnosis and the entire patient journey crucial for the management of the condition.
Increasing prevalence of these skin condition among children and young adult has contributed enormously towards seeking different modalities of treatment that are highly efficacious, and cost effective in nature. These growing demand for atopic dermatitis products have encouraged pharmaceutical manufacturers to invest in research and development and launch of new therapeutic products.
For instance, in November 2023, Almirall S.A., a biopharmaceutical company in medical dermatology received approval for EBGLYSS (lebrikizumab), from the European Commission (EC). EBGLYSS, is indicated for the treatment of adults suffering from moderate-to-severe atopic dermatitis (AD).
In addition to this, growing awareness among patients through education campaigns, and driven by the support of pharmaceutical manufacturers and regulatory agencies has expedited approvals and expanded indications for therapies further driving the demand for these drugs.
Hence, the rising prevalence of atopic dermatitis increasing spending in research and development to launch new product are key indicators driving the growth of the atopic dermatitis market.
Tier 1 companies comprise market leaders with a market revenue of above USD 100 million capturing significant market share of 15% to 20% in global market. These market leaders are characterized by wide range of product portfolio, and strong geographical presence across the globe.
These market leaders also differentiate themselves from the market based on the technology, and extensive expertise in manufacturing which have aided them in serving a wide range of consumer base. Prominent companies within tier 1 include Allergan Plc., Sanofi SA, Novartis and Bristol-Myers Squibb.
Tier 2 companies include mid-size players with revenue of USD 50 to 100 million. These players are characterized by their strong market knowledge and the technology that is being required for the manufacturing of these drugs. They ensure regulatory compliance but may be limited to their availability in certain markets. Prominent companies in tier 2 Meda Pharmaceuticals, Almirall, S.A and Regeneron Pharmaceuticals
Tier 3 includes the majority of companies that have limited geographical outreach or are operating at the local presence. These companies are focused towards fulfilling the demand of local market and are therefore classified as the tier 3 share segment.
They are comparatively small-scale players and are recognized as an unorganized market, which doesn’t have developed infrastructure and higher production capabilities.
The section below covers the industry analysis for the Atopic Dermatitis Treatment market for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Asia Pacific, Europe, and others, is provided.
The United States is anticipated to remain at the forefront in North America, and is projected to grow at a CAGR of 5.5% through 2034. In Asia Pacific, India is projected to witness a CAGR of 11.1% by 2034.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| Canada | 4.8% |
| Spain | 3.6% |
| France | 4.6% |
| South Korea | 5.6% |
| China | 9.1% |
| Australia | 7.1% |
Germany’s atopic dermatitis treatment market is poised to exhibit a CAGR of 5.4% between 2024 and 2034. Increasing cases of atopic dermatitis in Germany arising from environmental factors and genetic predispositions is significantly contributing to increase in demand for effective treatments.
Developments in pharmaceuticals, especially in biologics that are targeted at major immune pathways, is emphasizing towards revolutionization and the management of disease.
Growing patient awareness and proactive healthcare seeking behaviors play a major role in the early diagnosis and initiation of treatment, thereby bolstering market demand. Moreover, favorable regulatory environments for approval, commercialization, and establishment of new treatments against atopic dermatitis, further drives the growth of the market.
In addition, availability of well-built healthcare infrastructure issuing specialized dermatological services and innovative therapies to a large population, is thereby stimulates the market growth. These collective factors are fueling the growth of the atopic dermatitis market in the country.
In North America, the USA holds the maximum share of the global atopic dermatitis treatment industry. The USA market is anticipated to grow at a CAGR of 5.5% through 2034.
The market in USA is primarily driven by the increasing prevalence of atopic dermatitis, increasing investments in research and development to develop novel drug products and the growing demand for more effective therapies.
For instance, according to the statistics published by AllergyAsthmaNetwork.org in March 2023, atopic dermatitis affects over 16.5 million adults in the USA Increasing healthcare spending and improved accessibility of healthcare facilities offering better management of the disease condition majorly augments the growth of the market.
In addition, regulatory support extended by active agencies such as the FDA for approval of the new products accelerates the introduction of new generation of treatments to the market.
Rapid urbanization and changing lifestyles of Chinese population has significantly contributed to the rising prevalence of atopic dermatitis cases in the country. Increasing spending in health care, and growing investment of private players on expansion of their dermatological care are augmenting the growth of the market in the country.
Additionally, initiatives taken by Chinese government on increasing healthcare accessibility by providing general population with improved quality of care augments the growth of the market. Moreover, improved accessibility of healthcare in the underserved rural areas, further propels its market growth.
Moreover, increasing consumer awareness of symptoms and treatment, increasing number of players entering into the manufacturing and export of atopic dermatitis therapeutic products further drives the growth in the Chinese market.
All these factors taken together point to the fact that the AD market in China is getting bigger; and will surely grow further with enhanced health infrastructure and raised standards of patient care.
The section contains information about the leading segments in the industry. By drug class, the biologic therapy segment is estimated to account for 26.3% of the market share and is anticipated to witness significant growth during the forecast period.
| Drug Class | Biologic Therapy |
|---|---|
| Value Share (2024) | 26.3% |
The biologic therapy segment is projected to dominate the market in terms of revenue, and account for almost 26.3% of the market share in 2024. The segment holds highest share owing to its ability to specifically target and inhibit the mechanism of action of the pathogens.
These biologics are designed for targeting key molecules such as interleukins. This targeted approach often provides better outcomes as compared to the conventional treatments which makes the segment highly valuable. The rising prevalence of severe eczema cases and their growing awareness among individuals for its treatment has significantly augmented its growing demand in the market.
This growing demand has encouraged many of the manufacturers to focus on development of new biologics that have varied mechanism of action and improved safety profiles. Therefore, the efficacious treatment provided by these drugs with minimal side effects has contributed to its increased recommendation rate by the healthcare professionals.
| Mode of Administration | Topical |
|---|---|
| Value Share (2024) | 78.2% |
The topical segment is forecasted to account for a revenue share of over 78.2% in the atopic dermatitis treatment market by 2024 end. Recommendation of topical therapies such as corticosteroids, calcineurin inhibitors (like tacrolimus and pimecrolimus), and emollients as the first line treatments for the mild to moderate atomic dermatitis has significantly contributed to the segment growth.
In addition, its easy use, by the patient in their daily skincare routines, with the availability of variety of option at cost-effective prices has further augmented its market growth. Topically administered drugs are more affordable as compared to systemic therapies and biologics.
This cost-effective nature makes them accessible to the broader range of patients. In addition, its added advantage that it can be used from initial-flare-ups to long term maintenance makes them one of the preferred choice, for the management of chronic conditions. These are few of the factors that have significantly contributed topical route of administration to hold highest share of the market.
Key players operating in the atopic dermatitis treatment market are investing in development of advanced and innovative products that are more reliable and efficient. Also, many of the key players are emphasizing on launching new products to the market for expansion of their product portfolio and strengthening their market share.
Recent Industry Developments in Atopic Dermatitis Treatment Market:
| Report Attributes | Details |
|---|---|
| Current Total Market Size (2024) | USD 15.04 billion |
| Projected Market Size (2034) | USD 45.50 billion |
| CAGR (2024 to 2034) | 11.7% |
| Base Year for Estimation | 2023 |
| Historical Period | 2018 to 2023 |
| Projections Period | 2024 to 2034 |
| Market Analysis Parameters | Revenue in USD billion |
| by Product | Corticosteroids, Calcineurin Inhibitors, Immunosuppressants, Biologic Therapy, PDE-4 Inhibitor, Antibiotics, Antihistamines, Emollients |
| by Indication | Topical, Oral, Injectable |
| By End User | Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores, Mail Order Pharmacies, Dermatology Clinics |
| Regions Covered | North America, Latin America, East Asia, South Asia and Pacific, Western Europe, Eastern Europe, Middle East and Africa |
| Countries covered | United States, Japan, Germany, India, United Kingdom, France, Italy, Brazil, Canada, South Korea, Australia, Spain, Netherlands, Saudi Arabia, Switzerland |
| Key Players | Sanofi S.A., Galderma SA, Allergan Plc., Novartis, Bristol-Myers Squibb, Bayer AG, Meda Pharmaceuticals, Astellas Pharma Inc., Anacor Pharmaceutical Inc., Regeneron Pharmaceuticals |
| Additional Attributes | Emphasis on biologic therapies, increasing R&D investments, expansion in emerging markets, focus on pediatric treatments |
| Customization and Pricing | Available upon request |
In terms of product, the industry is divided into corticosteroids, calcineurin inhibitors, immunosuppressants, biologic therapy, pde-4 inhibitor, antibiotics, antihistamines and emollients.
In terms of indication, the industry is divided into topical, oral and injectable.
In terms of end user, the industry is divided into hospital pharmacies, retail pharmacies, online pharmacies, drug stores, mail order pharmacies, dermatology clinics
Key countries of North America, Latin America, Eastern Europe, Western Europe, East Asia, South Asia & Pacific, and Middle East and Africa (MEA), have been covered in the report.
The global Atopic Dermatitis Treatment cover industry is projected to witness CAGR of 11.7% between 2024 and 2034.
The global Atopic Dermatitis Treatment cover industry stood at USD 15.04 billion in 2024.
The global Atopic Dermatitis Treatment cover industry is anticipated to reach USD 45.50 billion by 2034 end.
India is set to record the highest CAGR of 11.1% in the assessment period.
The key players operating in the global Atopic Dermatitis Treatment cover industry include Sanofi SA, Novartis, Bristol-Myers Squibb, Bayer AG, Regeneron Pharmaceuticals are few of the key players in the atopic dermatitis treatment industry
Explore Similar Insights
Atopic Dermatitis Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
